We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Sangamo

News List

Sangamo Announces FDA Acceptance of IND Application for ST-920 Gene Therapy Candidate americanpharmaceuticalreview
February 21, 2019
Sangamo Therapeutics announced the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for ST-920...
Sangamo Announces Positive Preliminary Data from SB-525 Gene Therapy americanpharmaceuticalreview
August 10, 2018
Sangamo Therapeutics announced positive preliminary data from the Phase 1/2 clinical trial evaluating SB-525, a cDNA gene therapy candidate for Hemophilia A (Alta study).
Sangamo, Pfizer Deepen Relationship With New $162M ALS R&D Pact biospace
January 04, 2018
Earlier today, Sangamo Healing announced a $ 162 million agreement with Pfizer
Sangamo Announces Treatment of First Patient in SB-913 Trial americanpharmaceuticacreview
November 16, 2017
All three of Sangamo's in vivo genome editing product candidates have received Fast Track and Orphan Drug designations from the U.S.
Sangamo Receives Fast Track Designation from FDA americanpharmaceuticalreview
May 17, 2017
Sangamo Therapeutics announced the U.S. Food and Drug Administration (FDA) granted Fast Track designation to SB-525...

Previous page 1 2 Next page